Potent inhibition of protein-tyrosine phosphatase by phosphotyrosine-mimic containing cyclic peptides

Miki Akamatsu, Peter P. Roller, Li Chen, Zhong-Yin Zhang, Bin Ye, Terrence R. Burke

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

In an effort to derive potent and bioavailable protein-tyrosine phosphatase inhibitors, we have previously reported hexameric peptides based on the epidermal growth factor receptor sequence EGFR988 (Asp-Ala-Asp-Glu-Xxx-Leu, where Xxx = Tyr), in which the tyrosyl residue has been replaced by the non-hydrolyzable phosphotyrosyl mimics phosphonomethylphenylalanine (Pmp), difuorophosphonomethylphenylalanine (F2Pmp) and O-malonyltyrosine (OMT). Inhibitory potencies (IC50 values) of these peptides against the tyrosine phosphatase PTP 1B were 200, 0.2 and 10 μM, respectively. Since cellular penetration of peptides containing highly charged phosphonate residues is compromised, and good bioreversible protection strategies for the F2Pmp residue have not yet been reported, the OMT residue is of particular interest in that it affords potential new prodrug approaches. In the current study we have prepared cyclized versions of the OMT-containing EGFR988-993 peptide in order to increase its proteolytic stability and restrain conformational flexibility. Three different cyclic analogues were synthesized. Two of these were cyclized through the peptide backbone ('head to tail') using in one case a single glycine spacer (heptamer peptide) and in the second instance, two glycines (octamer peptide). In a PTP1-based assay the cyclic heptamer experienced a two-fold loss of potency (K(i) = 25.2 ± 3.9 μM) relative to the linear hexamer parent (K(i) = 13 ± 0.9 μM), while the cyclic octamer demonstrated a five-fold increase in potency (k(i) = 2.60 ± 0.11 pM). The third peptide was cyclized by means of a sulfide bridge between the side chain of a C-terminally added cysteine residue and the β-carbon of a N-terminal acetyl residue. Although the overall size of this ring was identical to that exhibited by the preceding backbone-cyclized octamer, it displayed a three-fold enhancement in potency (K(i) = 0.73 ± 0.03 μM). The structural basis for the observed results are discussed. Conformational restrictions induced by cyclization could aid in defining geometries for peptidomimetic design. Finally, it can be speculated that cyclization of other linear PTP-inhibitory peptides, such as the F2Pmp-containing hexamer, may also increase their potency.

Original languageEnglish (US)
Pages (from-to)157-163
Number of pages7
JournalBioorganic and Medicinal Chemistry
Volume5
Issue number1
DOIs
StatePublished - Jan 1997
Externally publishedYes

Fingerprint

Cyclic Peptides
Phosphotyrosine
Protein Tyrosine Phosphatases
Peptides
Cyclization
Glycine
Peptidomimetics
Organophosphonates
Prodrugs
Sulfides
Phosphoric Monoester Hydrolases
Epidermal Growth Factor Receptor
Inhibitory Concentration 50
Cysteine
Tyrosine
Assays
Carbon
Geometry

Keywords

  • Cyclic peptide
  • Inhibitor
  • Mimic
  • Phosphatase
  • Signal transduction

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Organic Chemistry
  • Drug Discovery
  • Pharmaceutical Science

Cite this

Potent inhibition of protein-tyrosine phosphatase by phosphotyrosine-mimic containing cyclic peptides. / Akamatsu, Miki; Roller, Peter P.; Chen, Li; Zhang, Zhong-Yin; Ye, Bin; Burke, Terrence R.

In: Bioorganic and Medicinal Chemistry, Vol. 5, No. 1, 01.1997, p. 157-163.

Research output: Contribution to journalArticle

Akamatsu, Miki ; Roller, Peter P. ; Chen, Li ; Zhang, Zhong-Yin ; Ye, Bin ; Burke, Terrence R. / Potent inhibition of protein-tyrosine phosphatase by phosphotyrosine-mimic containing cyclic peptides. In: Bioorganic and Medicinal Chemistry. 1997 ; Vol. 5, No. 1. pp. 157-163.
@article{4e8e2e609387494593de2d84e262c9d4,
title = "Potent inhibition of protein-tyrosine phosphatase by phosphotyrosine-mimic containing cyclic peptides",
abstract = "In an effort to derive potent and bioavailable protein-tyrosine phosphatase inhibitors, we have previously reported hexameric peptides based on the epidermal growth factor receptor sequence EGFR988 (Asp-Ala-Asp-Glu-Xxx-Leu, where Xxx = Tyr), in which the tyrosyl residue has been replaced by the non-hydrolyzable phosphotyrosyl mimics phosphonomethylphenylalanine (Pmp), difuorophosphonomethylphenylalanine (F2Pmp) and O-malonyltyrosine (OMT). Inhibitory potencies (IC50 values) of these peptides against the tyrosine phosphatase PTP 1B were 200, 0.2 and 10 μM, respectively. Since cellular penetration of peptides containing highly charged phosphonate residues is compromised, and good bioreversible protection strategies for the F2Pmp residue have not yet been reported, the OMT residue is of particular interest in that it affords potential new prodrug approaches. In the current study we have prepared cyclized versions of the OMT-containing EGFR988-993 peptide in order to increase its proteolytic stability and restrain conformational flexibility. Three different cyclic analogues were synthesized. Two of these were cyclized through the peptide backbone ('head to tail') using in one case a single glycine spacer (heptamer peptide) and in the second instance, two glycines (octamer peptide). In a PTP1-based assay the cyclic heptamer experienced a two-fold loss of potency (K(i) = 25.2 ± 3.9 μM) relative to the linear hexamer parent (K(i) = 13 ± 0.9 μM), while the cyclic octamer demonstrated a five-fold increase in potency (k(i) = 2.60 ± 0.11 pM). The third peptide was cyclized by means of a sulfide bridge between the side chain of a C-terminally added cysteine residue and the β-carbon of a N-terminal acetyl residue. Although the overall size of this ring was identical to that exhibited by the preceding backbone-cyclized octamer, it displayed a three-fold enhancement in potency (K(i) = 0.73 ± 0.03 μM). The structural basis for the observed results are discussed. Conformational restrictions induced by cyclization could aid in defining geometries for peptidomimetic design. Finally, it can be speculated that cyclization of other linear PTP-inhibitory peptides, such as the F2Pmp-containing hexamer, may also increase their potency.",
keywords = "Cyclic peptide, Inhibitor, Mimic, Phosphatase, Signal transduction",
author = "Miki Akamatsu and Roller, {Peter P.} and Li Chen and Zhong-Yin Zhang and Bin Ye and Burke, {Terrence R.}",
year = "1997",
month = "1",
doi = "10.1016/S0968-0896(96)00195-2",
language = "English (US)",
volume = "5",
pages = "157--163",
journal = "Bioorganic and Medicinal Chemistry",
issn = "0968-0896",
publisher = "Elsevier Limited",
number = "1",

}

TY - JOUR

T1 - Potent inhibition of protein-tyrosine phosphatase by phosphotyrosine-mimic containing cyclic peptides

AU - Akamatsu, Miki

AU - Roller, Peter P.

AU - Chen, Li

AU - Zhang, Zhong-Yin

AU - Ye, Bin

AU - Burke, Terrence R.

PY - 1997/1

Y1 - 1997/1

N2 - In an effort to derive potent and bioavailable protein-tyrosine phosphatase inhibitors, we have previously reported hexameric peptides based on the epidermal growth factor receptor sequence EGFR988 (Asp-Ala-Asp-Glu-Xxx-Leu, where Xxx = Tyr), in which the tyrosyl residue has been replaced by the non-hydrolyzable phosphotyrosyl mimics phosphonomethylphenylalanine (Pmp), difuorophosphonomethylphenylalanine (F2Pmp) and O-malonyltyrosine (OMT). Inhibitory potencies (IC50 values) of these peptides against the tyrosine phosphatase PTP 1B were 200, 0.2 and 10 μM, respectively. Since cellular penetration of peptides containing highly charged phosphonate residues is compromised, and good bioreversible protection strategies for the F2Pmp residue have not yet been reported, the OMT residue is of particular interest in that it affords potential new prodrug approaches. In the current study we have prepared cyclized versions of the OMT-containing EGFR988-993 peptide in order to increase its proteolytic stability and restrain conformational flexibility. Three different cyclic analogues were synthesized. Two of these were cyclized through the peptide backbone ('head to tail') using in one case a single glycine spacer (heptamer peptide) and in the second instance, two glycines (octamer peptide). In a PTP1-based assay the cyclic heptamer experienced a two-fold loss of potency (K(i) = 25.2 ± 3.9 μM) relative to the linear hexamer parent (K(i) = 13 ± 0.9 μM), while the cyclic octamer demonstrated a five-fold increase in potency (k(i) = 2.60 ± 0.11 pM). The third peptide was cyclized by means of a sulfide bridge between the side chain of a C-terminally added cysteine residue and the β-carbon of a N-terminal acetyl residue. Although the overall size of this ring was identical to that exhibited by the preceding backbone-cyclized octamer, it displayed a three-fold enhancement in potency (K(i) = 0.73 ± 0.03 μM). The structural basis for the observed results are discussed. Conformational restrictions induced by cyclization could aid in defining geometries for peptidomimetic design. Finally, it can be speculated that cyclization of other linear PTP-inhibitory peptides, such as the F2Pmp-containing hexamer, may also increase their potency.

AB - In an effort to derive potent and bioavailable protein-tyrosine phosphatase inhibitors, we have previously reported hexameric peptides based on the epidermal growth factor receptor sequence EGFR988 (Asp-Ala-Asp-Glu-Xxx-Leu, where Xxx = Tyr), in which the tyrosyl residue has been replaced by the non-hydrolyzable phosphotyrosyl mimics phosphonomethylphenylalanine (Pmp), difuorophosphonomethylphenylalanine (F2Pmp) and O-malonyltyrosine (OMT). Inhibitory potencies (IC50 values) of these peptides against the tyrosine phosphatase PTP 1B were 200, 0.2 and 10 μM, respectively. Since cellular penetration of peptides containing highly charged phosphonate residues is compromised, and good bioreversible protection strategies for the F2Pmp residue have not yet been reported, the OMT residue is of particular interest in that it affords potential new prodrug approaches. In the current study we have prepared cyclized versions of the OMT-containing EGFR988-993 peptide in order to increase its proteolytic stability and restrain conformational flexibility. Three different cyclic analogues were synthesized. Two of these were cyclized through the peptide backbone ('head to tail') using in one case a single glycine spacer (heptamer peptide) and in the second instance, two glycines (octamer peptide). In a PTP1-based assay the cyclic heptamer experienced a two-fold loss of potency (K(i) = 25.2 ± 3.9 μM) relative to the linear hexamer parent (K(i) = 13 ± 0.9 μM), while the cyclic octamer demonstrated a five-fold increase in potency (k(i) = 2.60 ± 0.11 pM). The third peptide was cyclized by means of a sulfide bridge between the side chain of a C-terminally added cysteine residue and the β-carbon of a N-terminal acetyl residue. Although the overall size of this ring was identical to that exhibited by the preceding backbone-cyclized octamer, it displayed a three-fold enhancement in potency (K(i) = 0.73 ± 0.03 μM). The structural basis for the observed results are discussed. Conformational restrictions induced by cyclization could aid in defining geometries for peptidomimetic design. Finally, it can be speculated that cyclization of other linear PTP-inhibitory peptides, such as the F2Pmp-containing hexamer, may also increase their potency.

KW - Cyclic peptide

KW - Inhibitor

KW - Mimic

KW - Phosphatase

KW - Signal transduction

UR - http://www.scopus.com/inward/record.url?scp=0031031166&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031031166&partnerID=8YFLogxK

U2 - 10.1016/S0968-0896(96)00195-2

DO - 10.1016/S0968-0896(96)00195-2

M3 - Article

VL - 5

SP - 157

EP - 163

JO - Bioorganic and Medicinal Chemistry

JF - Bioorganic and Medicinal Chemistry

SN - 0968-0896

IS - 1

ER -